Cargando…
A B‐Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies
BACKGROUND: B‐Raf V600E mutations account for about half of all skin cutaneous melanoma cases, and patients with this mutation are sensitive to BRAF inhibitors. However, aberrations in other genes in the MAPK/ERK pathway may cascade a similar effect as B‐Raf V600E mutations, rendering those patients...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855909/ https://www.ncbi.nlm.nih.gov/pubmed/35044091 http://dx.doi.org/10.1002/cam4.4491 |